Melane Sampson, Author at BioTuesdays

Developments

Fractyl reveals promising preclinical data for pancreatic gene therapy program

Fractyl Health (NASDAQ:GUTS) has announced that it will present new data from its RJVA-001 Rejuva Smart GLP-1 pancreatic gene therapy program for the treatment of obesity and type 2 diabetes (T2D) at the 22nd World...

December 12, 2024

Executive Moves

Rockwell names Jesse Neri as CFO

Rockwell Medical (NASDAQ:RMTI) announced the promotion of Jesse Neri to chief financial officer (CFO). Mr. Neri, formally Rockwell’s senior vice president of finance, joined the company in 2023, bringing more than 25...

December 12, 2024

Developments

Candel achieves primary endpoint in Phase 3 trial evaluating CAN-2409 in prostate cancer

Candel Therapeutics (NASDAQ:CADL) has announced results from its multicenter Phase 3 trial evaluating CAN-2409 viral immunotherapy in patients with localized prostate cancer. The study achieved its primary endpoint...

December 11, 2024

Developments

Akoya and NeraCare enter agreement to develop and commercialize Immunoprint test for melanoma

Akoya Biosciences (NASDAQ:AKYA) announced that it has entered into an exclusive global licencing agreement with NeraCare to develop and commercialize NeraCare’s Immunoprint test for guiding early-stage melanoma...

December 10, 2024

Developments

IN8bio reports sustained PFS in INB-100 trial for HSCT patients

IN8bio (NASDAQ:INAB) shared updated data showcasing continued progression-free survival (PFS) from its Phase 1 trial of INB-100 in older patients with hematologic malignancies undergoing haploidentical stem cell...

December 10, 2024

Developments

Immunovia announces positive results and strong accuracy of next-gen test for PDAC

Immunovia (STO:IMMNOV) has announced the completion of its CLARITI study, demonstrating positive outcomes and strong accuracy in the clinical validation of its next-generation test for the early detection of pancreatic...

December 9, 2024

Developments

BioNxt achieves milestones for BNT23001 in MS

BioNxt Solutions (CSE:BNXT; OTC PINK:BNXTF; FSE:BXT) has announced that key milestones have been achieved in the development of BNT23001 for the treatment of multiple sclerosis (MS). BNT23001 is BioNxt’s proprietary...

December 9, 2024

Developments

Innate to receive up to $7.9 million from IFLI to advance IPH6501 in FL

Innate Pharma (Euronext Paris:IPH; NASDAQ:IPHA) and the Institute for Follicular Lymphoma (IFLI) have announced a collaboration agreement to clinically evaluate the potential of Innate’s IPH6501 in follicular lymphoma...

December 6, 2024

Developments

FDA grants clearance for Nanox.ARC expanding application to pulmonary and general use

Nanox Imaging (NASDAQ:NNOX) has announced that its Nanox.ARC stationary X-ray system has received 510(k) clearance from the FDA, allowing general use including the human musculoskeletal system, pulmonary, intra...

December 6, 2024

Developments

Cartesian reports promising results from Phase 2b trial of Descartes-08 in MG

Cartesian Therapeutics (NASDAQ:RNAC) announced updated efficacy and safety data from its Phase 2b trial of Descartes-08 in myasthenia gravis (MG), showing deep, durable responses without the need for chemotherapy. The...

December 4, 2024

Author - Melane Sampson

Fractyl reveals promising preclinical data for pancreatic gene therapy program

Rockwell names Jesse Neri as CFO

Candel achieves primary endpoint in Phase 3 trial evaluating CAN-2409 in prostate cancer

Akoya and NeraCare enter agreement to develop and commercialize Immunoprint test for melanoma

IN8bio reports sustained PFS in INB-100 trial for HSCT patients

Immunovia announces positive results and strong accuracy of next-gen test for PDAC

BioNxt achieves milestones for BNT23001 in MS

Innate to receive up to $7.9 million from IFLI to advance IPH6501 in FL

FDA grants clearance for Nanox.ARC expanding application to pulmonary and general use

Cartesian reports promising results from Phase 2b trial of Descartes-08 in MG

Subscribe